Avanbulin

Avanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.4 μM. Avanbulin binds to tubulin with an apparent Kd value of 244 nM. Avanbulin can be used for the research of cancer and cell division[1][2][3][4].

Product Specifications

CAS Number

[798577-91-0]

Product Name Alternative

BAL27862

UNSPSC

12352005

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/avanbulin.html

Purity

99.08

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(N)C=C1)CN2C(C3=NON=C3NCCC#N)=NC4=CC=CC=C24

Molecular Formula

C20H17N7O2

Molecular Weight

387.39

References & Citations

[1]Prota AE, et al. The novel microtubule-destabilizing drug avanbulin binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol. 2014 Apr 17;426 (8) :1848-60.|[2]Kolb EA, et al. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62 (6) :1106-9.|[3]Bergès R, et al. The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells. Mol Cancer Ther. 2016 Nov;15 (11) :2740-2749.|[4]Dudka D, et al. Complete microtubule-kinetochore occupancy favours the segregation of merotelic attachments. Nat Commun. 2018;9 (1) :2042. Published 2018 May 23.